Literature DB >> 29842834

High-Throughput Flow Cytometry Drug Combination Discovery with Novel Synergy Analysis Software, SynScreen.

Dominique R Perez1,2, Bruce S Edwards1,2,3, Larry A Sklar1,2,3, Alexandre Chigaev1,2,3.   

Abstract

Classical therapeutic regimens are subject to toxicity, low efficacy, and/or the development of drug resistance. Thus, the discovery of synergistic drug combinations would permit treatment with lower, tolerable dosages of each agent and restored sensitivity. We describe the development and use of the SynScreen software application, which allows for visual and mathematical determinations of compound concentrations that produce super-additive effects. This software uses nonlinear regression fits of dose responses to determine synergism by the Bliss independence and Loewe additivity analysis models. We demonstrate the utility of SynScreen with data analysis from in vitro high-throughput flow cytometry (HTFC) combination screens with repurposed drugs and multiplexed synergy analysis of multiple biologic parameters in parallel. The applicability of SynScreen was confirmed by testing open-source data sets used in published drug combination literature. A key benefit of SynScreen for high-throughput drug combination screening is that observed measurements are graphically depicted in comparison with a three-dimensional surface that represents the theoretical responses at which Bliss additivity would occur. These images and summary tables for the calculated drug interactions are automatically exported. This allows for substantial data sets to be visually assessed, expediting the quick identification of efficacious drug combinations and thereby facilitating the design of confirmatory studies and clinical trials.

Entities:  

Keywords:  drug combinations; drug interactions; high-throughput flow cytometry (HTFC); synergy

Mesh:

Year:  2018        PMID: 29842834      PMCID: PMC6363001          DOI: 10.1177/2472555218775913

Source DB:  PubMed          Journal:  SLAS Discov        ISSN: 2472-5552            Impact factor:   3.341


  16 in total

1.  The problem of synergism and antagonism of combined drugs.

Authors:  S LOEWE
Journal:  Arzneimittelforschung       Date:  1953-06

2.  Functional classification of drugs by properties of their pairwise interactions.

Authors:  Pamela Yeh; Ariane I Tschumi; Roy Kishony
Journal:  Nat Genet       Date:  2006-03-19       Impact factor: 38.330

3.  Drug combination studies and their synergy quantification using the Chou-Talalay method.

Authors:  Ting-Chao Chou
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

4.  High-throughput cytotoxicity screening by propidium iodide staining.

Authors:  Bruce S Edwards; Irena Ivnitski-Steele; Susan M Young; Virginia M Salas; Larry A Sklar
Journal:  Curr Protoc Cytom       Date:  2007-07

5.  Genotype-selective combination therapies for melanoma identified by high-throughput drug screening.

Authors:  Matthew A Held; Casey G Langdon; James T Platt; Tisheeka Graham-Steed; Zongzhi Liu; Ashok Chakraborty; Antonella Bacchiocchi; Andrew Koo; Jonathan W Haskins; Marcus W Bosenberg; David F Stern
Journal:  Cancer Discov       Date:  2012-12-13       Impact factor: 39.397

Review 6.  Flow Cytometry: Impact on Early Drug Discovery.

Authors:  Bruce S Edwards; Larry A Sklar
Journal:  J Biomol Screen       Date:  2015-03-24

7.  High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.

Authors:  Lesley A Mathews Griner; Rajarshi Guha; Paul Shinn; Ryan M Young; Jonathan M Keller; Dongbo Liu; Ian S Goldlust; Adam Yasgar; Crystal McKnight; Matthew B Boxer; Damien Y Duveau; Jian-Kang Jiang; Sam Michael; Tim Mierzwa; Wenwei Huang; Martin J Walsh; Bryan T Mott; Paresma Patel; William Leister; David J Maloney; Christopher A Leclair; Ganesha Rai; Ajit Jadhav; Brian D Peyser; Christopher P Austin; Scott E Martin; Anton Simeonov; Marc Ferrer; Louis M Staudt; Craig J Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

8.  Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy.

Authors:  Adam C Palmer; Peter K Sorger
Journal:  Cell       Date:  2017-12-14       Impact factor: 41.582

9.  Chemical combination effects predict connectivity in biological systems.

Authors:  Joseph Lehár; Grant R Zimmermann; Andrew S Krueger; Raymond A Molnar; Jebediah T Ledell; Adrian M Heilbut; Glenn F Short; Leanne C Giusti; Garry P Nolan; Omar A Magid; Margaret S Lee; Alexis A Borisy; Brent R Stockwell; Curtis T Keith
Journal:  Mol Syst Biol       Date:  2007-02-27       Impact factor: 11.429

10.  Combenefit: an interactive platform for the analysis and visualization of drug combinations.

Authors:  Giovanni Y Di Veroli; Chiara Fornari; Dennis Wang; Séverine Mollard; Jo L Bramhall; Frances M Richards; Duncan I Jodrell
Journal:  Bioinformatics       Date:  2016-04-25       Impact factor: 6.937

View more
  1 in total

1.  Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib.

Authors:  Myles Vigoda; Chase Mathieson; Nathaniel Evans; Carolyn Hale; Jennifer Jennings; Olivia Lucero; Sophia Jeng; Daniel Bottomly; Daniel Clayburgh; Peter Andersen; Ryan Li; Daniel Petrisor; Jeffrey W Tyner; Shannon McWeeney; Molly Kulesz-Martin
Journal:  Cancer Biol Ther       Date:  2022-12-31       Impact factor: 4.875

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.